verified SJR 5,823 · Q1 • database Scopus / SJR & Web of Science indexed

United States · Elsevier B.V.

workspace_premium Q1 — Cell Biology visibility_off Single Blind Peer Review lock_open Open Access Unclaimed

Blood

Blood, the official journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Acceptance of manuscri...

ISSN: 0006-4971

Editorial: Elsevier B.V.

Category: Cell Biology

Indexation: verifiedScopus / SJR verifiedWeb of Science

Unclaimed profile — some fields may be incomplete.

open_in_new Portal NPD menu_book Guía para Autores (Guidelines)

schedule Datos CoP · solo campos en BD

SJR Impact Factor trending_up

5,823 Q1

H-index 540

Tasa de Aceptación pie_chart

15% Alta selectividad

Fuente Acceptance_Rate

Tiempo a publicación hourglass_top

NPD

Campo Sin dato

Coste de Publicación (APC) payments

3.170 € Open Access

Ruta Non-OA 910 €

Metrics

Campos Scimago / CoP — sin series inventadas

Scopus / SJR Web of Science

SJR Impact

5,823

H-index

540

Docs (year)

859

Docs 3y

2584

Total refs

27230

Cites 3y

19324

Citable 3y

1536

Cites/Doc 2y

7.31

Ref/Doc

31.7

Immediate OA

3170 €

Embargoed OA

NPD

Non OA / Submission

910 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients

Tumor necrosis factor SNP haplotypes are associated with iron deficiency anemia in West African children

CNS Hodgkin lymphoma

Clonotypic B cells in classic Hodgkin lymphoma

Circulating clonotypic B cells in classic Hodgkin lymphoma

Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients

Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma

Chloroquine treatment affects T-cell priming to minor histocompatibility antigens and graft-versus-host disease

Cell-surface trafficking and release of flt3 ligand from T lymphocytes is induced by common cytokine receptor gamma-chain signaling and inhibited by cyclosporin A

Busulfan bioavailability

Brentuximab Vedotin Plus ESHAP (BRESHAP) Is a Highly Effective Combination for Inducing Remission in Refractory and Relapsed Hodgkin Lymphoma Patients Prior to Autologous Stem Cell Transplant: A Trial of the Spanish Group of Lymphoma and Bone Marrow

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

SHOW MORE ARTICLES

Bleeding in patients receiving vitamin K antagonists who would have been excluded from trials on which the indication for anticoagulation was based

A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32

Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial

Atypical prediagnosis Epstein-Barr virus serology restricted to EBV-positive Hodgkin lymphoma

Allogeneic Stem Cell Transplantation from Unrelated Donors after Reduced Intensity Conditioning in Patients with MDS/sAML. A Report from the Chronic Leukemia Working Party (CLWP) of the EBMT.

Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation

AHOD0031: A Phase III Study of Dose-Intensive Therapy for Intermediate Risk Hodgkin Lymphoma: A Report From the Children's Oncology Group

Advanced Stage Classical Hodgkin Lymphoma Patients with a Negative PET-Scan Following Treatment with ABVD Have Excellent Outcomes without the Need for Consolidative Radiotherapy Regardless of Disease Bulk at Presentation

A switch in infected erythrocyte deformability at the maturation and blood circulation of Plasmodium falciparum transmission stages

A specific role of integrin Mac-1 in accelerated macrophage efflux to the lymphatics

A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low Risk Hodgkin Lymphoma (HL)

A Phase 1b Study Investigating the Combination of the Tetravalent Bispecific NK Cell Engager AFM13 and Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

FAQS

In Country of Papers you can find SJR impact factor and other metrics to help you decide on a Journal.